Sarepta director granted 16,875 RSU shares

Boor Kathryn Jean reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Boor Kathryn Jean reported acquisition or exercise transactions in this Form 4 filing.

Sarepta Therapeutics, Inc. director Kathryn Jean Boor received an equity grant in the form of restricted stock units. She was granted 16,875 RSUs, each representing one share of common stock, at no cash cost. The RSUs vest on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year's meeting. Following this grant, she directly holds 25,138 shares of common stock.

Insider Trade Summary

Grant/Award: 16,875 shares

Grant/Award 1 txn

Insider Boor Kathryn Jean

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	16,875	$0.00	$0.00

Holdings After Transaction: Common Stock — 25,138 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

Key Figures

RSU grant size: 16,875 shares Grant price: $0.0000 per share Shares after grant: 25,138 shares

3 metrics

RSU grant size 16,875 shares Restricted stock units granted to director on 2026-06-04

Grant price $0.0000 per share Reported transaction price per RSU share

Shares after grant 25,138 shares Total common stock held directly following transaction

Key Terms

restricted stock units ("RSUs"), annual meeting of stockholders, vest

3 terms

restricted stock units ("RSUs") financial

"The Reporting Person was granted restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

annual meeting of stockholders financial

"The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders"

vest financial

"The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta Therapeutics (SRPT) report for Kathryn Jean Boor?

Sarepta reported that director Kathryn Jean Boor received a grant of 16,875 restricted stock units. Each RSU represents one share of common stock and was granted as equity compensation, not through an open-market purchase.

How many Sarepta Therapeutics (SRPT) shares were granted to the director in this Form 4?

The Form 4 shows a grant of 16,875 restricted stock units to director Kathryn Jean Boor. Each RSU corresponds to one share of Sarepta common stock, increasing her direct holdings when the units vest.

What is the vesting schedule for Kathryn Jean Boor’s RSUs at Sarepta Therapeutics (SRPT)?

The RSUs vest on the earlier of one year from the grant date or the next annual stockholder meeting that occurs at least 50 weeks after the prior year’s meeting. Vesting must occur before the units convert into shares.

Did Kathryn Jean Boor pay a purchase price for her Sarepta Therapeutics (SRPT) RSU grant?

No cash purchase price was paid for the grant, as the transaction price per share is reported as 0.0000. This indicates the award is compensation-based rather than an open-market stock purchase.

How many Sarepta Therapeutics (SRPT) shares does Kathryn Jean Boor hold after this RSU grant?

After the reported grant, Kathryn Jean Boor directly holds 25,138 shares of Sarepta common stock. This total reflects her position following the addition of the 16,875 restricted stock units disclosed in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 08:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boor Kathryn Jean

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		16,875	A	(1)	25,138	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest on earlier of the one-year anniversary of the date of grant and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Kathryn Boor	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)